ArticleEuropean journal of nuclear medicine and molecular imaging2010
Highlights of the EANM Congress Barcelona 2009: increasing our impact in diagnostic imaging.
Article in European journal of nuclear medicine and molecular imaging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EANM Congress 2009 took place in Barcelona from 10 to 14 October under the chairmanship of Dr. Martin-Comin. As always, the meeting was successful with high-level scientific content and a great number of participants. In spite of the economic crisis, industry made an important contribution presenting new revolutionary equipment and tracers, and in particular the pharmaceutical industry has increased its involvement in our speciality. This article is a brief summary of the major scientific contributions presented at the annual congress 2009, highlighting the fields of nuclear medicine at a higher level of development, including those with an increased clinical impact (especially oncology, but also cardiology, neurology and other clinical sciences), new detectors and multimodality imaging, and those fields showing important progress, including radiochemistry and pharmacy (with the development of new tracers and increased collaboration of industry).
Indexed as
Identifiers
20198475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.